Updated on 10 June 2015
The test from Roche, will identify a specific genetic variation from patients with recent ACS and aid in determining if a patient is eligible to receive the therapeutic
Singapore: Roche Diagnostics, a leading diagnostic and pharmaceutical firm, announced collaboration with DalCor Pharmaceuticals to develop a companion diagnostic (CDx) test for for a coronary heart syndrome.
The drug is dalcetrapib, a therapeutic from DalCor, is an investigational medicine that showed potential to reduce cardiovascular morbidity and mortality by as much as 39 percent in patients with a specific genetic profile.
As per the deal, CDx test from Roche will be used in a phase III clinical trial that will seek to validate the clinical efficacy of dalcetrapib, in patients who have experienced a recent Acute Coronary Syndrome (ACS) event.
"The possibility of reducing morbidity and mortality for patients who have experienced ACS by identifying genetic markers that can respond to therapy, is an exciting prospect and one that we are eager to be a part of," said, Mr Robert McNeil, CEO, DalCor Pharmaceuticals. "The DalCor and Roche collaboration for the genetic testing is the right combination for successful execution of the phase III trial."
Mr Paul Brown, head of Roche Molecular Diagnostics, said, "At Roche, we understand the importance of forging partnerships that make significant impacts on patient lives. Our first companion diagnostic test in cardiovascular disease represents a significant innovation, and leverages our expertise in developing FDA approved CDx tests. Working with DalCor is a good opportunity for us to enter this market and deliver on our mission of personalized healthcare."